1. Home
  2. RGEN vs PATH Comparison

RGEN vs PATH Comparison

Compare RGEN & PATH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RGEN
  • PATH
  • Stock Information
  • Founded
  • RGEN 1981
  • PATH 2005
  • Country
  • RGEN United States
  • PATH United States
  • Employees
  • RGEN N/A
  • PATH N/A
  • Industry
  • RGEN Medical/Dental Instruments
  • PATH Computer Software: Prepackaged Software
  • Sector
  • RGEN Health Care
  • PATH Technology
  • Exchange
  • RGEN Nasdaq
  • PATH Nasdaq
  • Market Cap
  • RGEN 6.5B
  • PATH 6.5B
  • IPO Year
  • RGEN N/A
  • PATH 2021
  • Fundamental
  • Price
  • RGEN $145.83
  • PATH $14.63
  • Analyst Decision
  • RGEN Buy
  • PATH Hold
  • Analyst Count
  • RGEN 11
  • PATH 17
  • Target Price
  • RGEN $167.90
  • PATH $13.44
  • AVG Volume (30 Days)
  • RGEN 929.7K
  • PATH 21.8M
  • Earning Date
  • RGEN 11-11-2025
  • PATH 09-04-2025
  • Dividend Yield
  • RGEN N/A
  • PATH N/A
  • EPS Growth
  • RGEN N/A
  • PATH N/A
  • EPS
  • RGEN N/A
  • PATH 0.04
  • Revenue
  • RGEN $673,956,000.00
  • PATH $1,496,651,000.00
  • Revenue This Year
  • RGEN $16.77
  • PATH $13.59
  • Revenue Next Year
  • RGEN $13.79
  • PATH $7.76
  • P/E Ratio
  • RGEN N/A
  • PATH $401.63
  • Revenue Growth
  • RGEN 8.73
  • PATH 8.25
  • 52 Week Low
  • RGEN $102.97
  • PATH $9.38
  • 52 Week High
  • RGEN $182.52
  • PATH $15.93
  • Technical
  • Relative Strength Index (RSI)
  • RGEN 68.33
  • PATH 72.63
  • Support Level
  • RGEN $121.25
  • PATH $12.61
  • Resistance Level
  • RGEN $125.90
  • PATH $14.94
  • Average True Range (ATR)
  • RGEN 5.31
  • PATH 0.71
  • MACD
  • RGEN 2.79
  • PATH 0.24
  • Stochastic Oscillator
  • RGEN 84.15
  • PATH 85.64

About RGEN Repligen Corporation

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.

About PATH UiPath Inc.

UiPath Inc offers an end-to-end cross-application enterprise automation platform principally with computer vision technology and user interface automations in its initial RPA offering, which remains the foundation of the platform. The platform leverages a range of automation technologies including robotic process automation, application programming interface, and artificial intelligence. UiPath's solution can automate a broad range of repetitive tasks across industries including claims processing, employee onboarding, invoice to cash, loan applications, and customer service.

Share on Social Networks: